Large genetic study links GLP-1 receptor activation to improved mental well-being

A new study provides evidence that activating the GLP-1 receptor, the biological target of popular weight-loss and diabetes medications, is associated with better mental health and a lower risk of conditions like depression and bipolar disorder. The research also suggests a potential protective effect against substance use disorders, hinting at psychiatric benefits that go beyond simple weight loss. These findings were published in Translational Psychiatry.

The glucagon-like peptide-1 (GLP-1) receptor is a protein found on the surface of cells in various parts of the body, including the pancreas and the brain. When activated, it helps regulate blood sugar and sends fullness signals to the brain, reducing appetite. Medications that activate this receptor, known as GLP-1 receptor agonists, have become widely used for managing type 2 diabetes and obesity. Because these drugs act on the central nervous system, scientists have been investigating whether they might also influence mental health.

Early clinical research hinted at potential psychiatric benefits. For instance, an early 2016 clinical study found that the GLP-1 medication liraglutide improved cognitive problems in patients with mood disorders. Following up on that, a 2017 experimental study showed that GLP-1 treatment produced physical changes in brain areas that regulate mood in people with mood disorders. More recently, a 2023 review of clinical trials showed that GLP-1 drugs can reliably reduce symptoms of depression.

These observations prompted researchers to ask whether activating the GLP-1 receptor genuinely protects against psychiatric and substance use disorders, or if the mood improvements were simply a side effect of patients feeling better about losing weight. To answer this, a research team led by Guoyi Yang conducted a large-scale genetic study to isolate the biological effects of GLP-1 receptor activation.

“GLP-1R agonists, such as semaglutide, have transformed how we treat obesity and type 2 diabetes,” said Yang, a postdoctoral researcher at the Division of Translational Medicine and Human Genetics, Department of Medicine at the University of Pennsylvania. “Concerns were raised about the risk of suicidal ideation and self-injury in people using GLP-1R agonists. In contrast, clinical trials suggested that these medications reduced depressive symptoms. To better understand the psychiatric effects of GLP-1R agonists, we used genetic variants as proxies for GLP-1R activation, the intended target of these drugs, to evaluate whether activating this receptor influences mental health outcomes,” he told PsyPost.

The researchers used a technique called Mendelian randomization. This method acts like a natural clinical trial by looking at genetic variations that people are born with. Because genes are assigned randomly at birth and are not influenced by lifestyle choices or environmental factors, they can help establish whether a specific biological mechanism directly influences an outcome. The team focused on specific genetic variants near the GLP1R gene that mimic the effects of taking a GLP-1 drug.

This approach uses genetics to predict what happens when you intervene on a specific biological target. “Our research uses genetics as a tool to predict the impact of GLP-1R activation – we aren’t saying that GLP-1R activation is only relevant to people with a certain genetic background,” Yang explained. “We hypothesize that the genetic variants that we consider in this paper affect the same mechanism that the drug affects – and so the genetic variants tell us what happens if you intervene on this target using the drug.”

Yang and colleagues identified two sets of these natural genetic proxies. The first set lowers body mass index, which is a common measure of body fat based on a person’s height and weight. The second set lowers glycated hemoglobin (HbA1c), which is a measure of average blood sugar levels over several months. They analyzed data from massive genetic databases, including the UK Biobank, which contained information from hundreds of thousands of people of European ancestry. The researchers examined how these GLP-1-activating genetic variants related to a broad spectrum of mental health outcomes.

The mental health outcomes included general well-being, comprising life satisfaction, positive affect, neuroticism, and depressive symptoms. The researchers also looked at diagnosed mental health disorders like major depressive disorder, bipolar disorder, schizophrenia, and attention deficit hyperactivity disorder (ADHD). Finally, they examined the risk of substance use disorders, such as alcohol dependence and cannabis use disorder. To ensure their results were robust, they compared the effects of the specific GLP-1 variants against general genetic variants from across the entire genome that simply lower body weight or blood sugar.

The findings indicate that genetically predicted GLP-1 receptor activation through the body mass index pathway is associated with widespread mental health benefits. Specifically, for every 1-kilogram per square meter decrease in body mass index driven by GLP-1 receptor activation, individuals experienced a 0.06 standard deviation improvement in overall mental well-being. This included higher life satisfaction and lower levels of neuroticism and depressive symptoms.

The researchers also found a reduced risk for severe psychiatric conditions. A 1-kilogram per square meter decrease in body mass index via the GLP-1 pathway was associated with an odds ratio of 0.82 for major depressive disorder, meaning a roughly 18% lower risk. The association with bipolar disorder was even stronger, showing an odds ratio of 0.61, or a 39% reduction in risk. There was also suggestive evidence that this specific biological pathway lowers the risk of ADHD and postpartum depression.

“We were surprised by just how broadly GLP-1R activation seems to benefit mental health, extending to depression, bipolar disorder, and potentially substance use disorders,” Yang said. “The effect on bipolar disorder was striking, showing almost a 40% lower risk (odds ratio of 0.61). These results highlight GLP-1R agonists as promising candidates for future psychiatric therapies.”

Notably, these mental health benefits were much stronger than the effects seen from general, genome-wide genetic variants that just lower body mass index. This suggests that the psychiatric advantages of GLP-1 receptor activation are not entirely explained by weight loss alone. The receptor’s direct activity in the brain, potentially regulating stress responses and neuroinflammation, likely plays an independent role in improving mood. Interestingly, genetic variants that mimicked the blood-sugar-lowering effects of GLP-1 activation did not show these same broad mental health benefits.

The study also provided suggestive evidence that GLP-1 receptor activation is associated with a lower risk of substance use disorders and fewer reported alcohol problems. These findings are in line with research covered by PsyPost in 2025, which examined actual prescription records and hospitalizations rather than genetic proxies, and similarly found evidence linking GLP-1 pathway activity to a lower risk of substance use disorders.

The new results are also consistent with another study covered by PsyPost in 2026. That study, which also used Mendelian randomization to analyze genetic proxies for GLP-1 receptor activation, found no evidence of increased risk for major psychiatric conditions like depression and bipolar disorder, alleviating early concerns that the medications might provoke psychiatric distress.

As with all research, there are a few things to keep in mind when interpreting the results. The Mendelian randomization approach relies on the assumption that the selected genetic variants only affect the outcomes through the GLP-1 receptor. It is possible that these specific genes also influence neighboring biological pathways, which could independently affect mental health. The researchers used statistical tests to check for this, but the possibility cannot be completely ruled out.

“A key limitation of this method (Mendelian randomization) is that it relies on rigorous assumptions that cannot be verified,” Yang pointed out. “While we carefully selected genetic variants in or near GLP1R to mimic the drug target, we cannot rule out the possibility that nearby genes might also play a role. Clinical trials are needed to determine whether these psychiatric benefits directly translate to patients.”

Additionally, looking at genetic variants measures the effect of lifelong exposure to slightly altered GLP-1 receptor activity. This is quite different from an adult taking a concentrated, high-dose medication over a few months or years. While the genetic data suggests that activating this pathway is safe and potentially beneficial for mental health over a lifetime, clinical trials are needed to confirm whether GLP-1 medications produce these exact psychiatric benefits in real-world patients.

“The effect size reflects the lifelong genetic effect of GLP-1R activation in the general population,” Yang noted. “In contrast, patients in the real world usually take GLP-1R agonists for shorter periods. Therefore, our numbers should not be viewed as the exact risk reduction patients will experience when taking these medications.”

Looking ahead, the research team aims to dive deeper into how these medications work in the body. “Our immediate next step is to understand the biological mechanisms underlying these psychiatric effects of GLP-1R activation,” Yang said. “In the long term, our goal is to define the multifaceted effects of GLP-1R agonists across organs and to identify novel, genetically validated drug targets for cardiovascular, kidney, and metabolic diseases.”

You can follow Yang’s work on X (formerly Twitter) at @yanggy_hku.

The study, “Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization study,” was authored by Guoyi Yang, Stephen Burgess, and C. Mary Schooling.